{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T15:50:38Z","timestamp":1760889038449},"reference-count":21,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2015,8,7]],"date-time":"2015-08-07T00:00:00Z","timestamp":1438905600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Haemophilia"],"published-print":{"date-parts":[[2016,1]]},"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Central venous access devices (<jats:styled-content style=\"fixed-case\">CVAD<\/jats:styled-content>s) are used in the care of paediatric haemophilic patients with difficult peripheral access, but their use is limited by complications such as infection. We previously published our experience with monthly recombinant tissue plasminogen activator (r\u2010tPA) administration to <jats:styled-content style=\"fixed-case\">CVAD<\/jats:styled-content>s of haemophilic patients as an intervention for infection prophylaxis, which suggested a 10\u2010fold decrease in infection rate compared to published rates without r\u2010tPA.<\/jats:p><\/jats:sec><jats:sec><jats:title>Aim<\/jats:title><jats:p>This study was conducted to assess the <jats:styled-content style=\"fixed-case\">CVAD<\/jats:styled-content> infection rate in an expanded haemophilia cohort receiving r\u2010tPA over an extended period.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A retrospective review was performed on patients with haemophilia who received monthly r\u2010tPA to <jats:styled-content style=\"fixed-case\">CVAD<\/jats:styled-content>s, with data collected from January 1, 2008 to December 31, 2012. The data were merged with the previously reported data set (collected from June 1, 1998 to December 31, 2007).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Over the entire observation period, there were 46\u00a0350 <jats:styled-content style=\"fixed-case\">CVAD<\/jats:styled-content> days among 32 patients [26 severe factor VIII (FVIII) deficiency, six severe FIX deficiency]. Eight patients received immune tolerance therapy for inhibitors and 24 patients received prophylactic factor administration. No patients were <jats:styled-content style=\"fixed-case\">HIV<\/jats:styled-content> positive. Three infections were observed, with an overall infection rate of 0.06 infections per 1000 <jats:styled-content style=\"fixed-case\">CVAD<\/jats:styled-content> days.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>A low <jats:styled-content style=\"fixed-case\">CVAD<\/jats:styled-content> infection rate, similar to that observed in our previous study (0.04 per 1000 <jats:styled-content style=\"fixed-case\">CVAD<\/jats:styled-content> days), was observed in this expanded haemophilia cohort treated with prophylactic r\u2010tPA, supporting the use of monthly r\u2010tPA as <jats:styled-content style=\"fixed-case\">CVAD<\/jats:styled-content> infection prophylaxis in haemophilia patients.<\/jats:p><\/jats:sec>","DOI":"10.1111\/hae.12772","type":"journal-article","created":{"date-parts":[[2015,8,7]],"date-time":"2015-08-07T07:42:56Z","timestamp":1438933376000},"page":"81-86","source":"Crossref","is-referenced-by-count":5,"title":["Updated analysis: central venous access device infection rates in an expanded cohort of paediatric patients with severe haemophilia receiving prophylactic recombinant tissue plasminogen activator"],"prefix":"10.1111","volume":"22","author":[{"given":"C. E.","family":"McCarthy","sequence":"first","affiliation":[{"name":"Department of Pediatrics Stanford University School of Medicine Palo Alto CA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"O'Brien","sequence":"additional","affiliation":[{"name":"Cancer and Blood Disorders Institute Cincinnati Children's Hospital Medical Center Cincinnati OH USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Andrews","sequence":"additional","affiliation":[{"name":"Department of Pediatrics Stanford University School of Medicine Palo Alto CA USA"},{"name":"Department of Pathology Stanford University School of Medicine Palo Alto CA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. M.","family":"Zoland","sequence":"additional","affiliation":[{"name":"Department of Pediatrics Stanford University School of Medicine Palo Alto CA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Macasiray","sequence":"additional","affiliation":[{"name":"Department of Pediatrics Stanford University School of Medicine Palo Alto CA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W.","family":"Wong","sequence":"additional","affiliation":[{"name":"Department of Pediatrics Stanford University School of Medicine Palo Alto CA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Lo","sequence":"additional","affiliation":[{"name":"Department of Pediatrics Stanford University School of Medicine Palo Alto CA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Glader","sequence":"additional","affiliation":[{"name":"Department of Pediatrics Stanford University School of Medicine Palo Alto CA USA"},{"name":"Department of Pathology Stanford University School of Medicine Palo Alto CA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Tamaresis","sequence":"additional","affiliation":[{"name":"Department of Health Research and Policy Stanford University School of Medicine Palo Alto CA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Jeng","sequence":"additional","affiliation":[{"name":"Department of Pediatrics Stanford University School of Medicine Palo Alto CA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2015,8,7]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa067659"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2010.08469.x"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2796.1992.tb00546.x"},{"key":"e_1_2_7_5_1","unstructured":"National Hemophilia Foundation.Medical and Scientific Advisory Council (MASAC) Recommendations Concerning Prophylaxis: Regular Administration of Clotting Factor Concentrate to Prevent Bleeding.New York 2007(document #179)."},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2011.02554.x"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2516.2003.00840.x"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/jpc.12112"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2012.02774.x"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.24401"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2010.10.001"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2010.02347.x"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2009.02075.x"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.12241"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0084869"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.21095"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2007.01599.x"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2009.02063.x"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajic.2008.03.002"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/0010-4825(92)90023-G"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1011376"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2011.02739.x"}],"container-title":["Haemophilia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fhae.12772","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/hae.12772","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,24]],"date-time":"2023-09-24T09:27:28Z","timestamp":1695547648000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/hae.12772"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,8,7]]},"references-count":21,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,1]]}},"alternative-id":["10.1111\/hae.12772"],"URL":"https:\/\/doi.org\/10.1111\/hae.12772","archive":["Portico"],"relation":{},"ISSN":["1351-8216","1365-2516"],"issn-type":[{"value":"1351-8216","type":"print"},{"value":"1365-2516","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,8,7]]}}}